Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults Pharmaceutical Investing
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS APPH, BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
Universal Ibogaine Announces Engagement of Media and Investor Relations Advisors Pharmaceutical Investing
New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States Pharmaceutical Investing
Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx for Acute Myocarditis Pharmaceutical Investing
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting Pharmaceutical Investing
Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. Pharmaceutical Investing
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis Pharmaceutical Investing
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors Pharmaceutical Investing
Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection Pharmaceutical Investing
Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults Pharmaceutical Investing
